Autonomix Medical Reports Increased Losses and Need for Additional Capital

Autonomix Medical, Inc. reported its financial results for the three and nine months ended December 31, 2025, revealing a net loss of $3.3 million for the quarter and $14.0 million for the nine-month period, compared to losses of $2.7 million and $8.2 million, respectively, in the same periods of the previous year. The company, which has yet to generate revenue, attributed the increased losses primarily to higher research and development expenses, which rose by 65% to $1.7 million for the quarter and by 79% to $5.7 million for the nine months, driven by costs associated with clinical trials and product development.

Total operating expenses for the quarter increased by 22% to $3.3 million, while for the nine months, they surged by 72% to $14.3 million. General and administrative expenses saw a slight decrease of 5% for the quarter but increased by 67% for the nine-month period, reflecting higher stock-based compensation and legal fees. The company reported cash and cash equivalents of $9.9 million as of December 31, 2025, with working capital of $8.5 million, indicating a need for additional capital to sustain operations beyond the third quarter of 2026.

In terms of strategic developments, Autonomix has made significant progress in its clinical studies, including the completion of a first-in-human proof-of-concept study for its catheter-based solution targeting pancreatic cancer pain. The company has initiated a follow-on study to expand its clinical trials to include patients with other visceral cancers. Additionally, Autonomix has secured new patents in the U.S. and Europe for its technology, enhancing its intellectual property portfolio and supporting its development in cardiology applications.

Operationally, the company has focused on advancing its product development, completing key verification and validation activities for its ablation catheter. The company also reported an increase in its employee headcount, reflecting its ongoing efforts to bolster its operational capabilities. However, it continues to face challenges related to its internal controls, which have been identified as ineffective due to material weaknesses, prompting management to implement additional measures to improve financial reporting and compliance.

Looking ahead, Autonomix anticipates needing to raise between $30 million and $36 million to fund its operations through the commercialization of its first indication. The company acknowledges the uncertainty surrounding the timing and costs of clinical trials and the potential need to adjust its business plan if sufficient capital cannot be secured. The outlook remains cautious, with management emphasizing the importance of securing additional financing to support ongoing development and regulatory efforts.